Ascendis Pharma A/S (ASND) Competitors

argenx (NASDAQ:ARGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.

Which has more volatility and risk, ARGX or ASND?

argenx has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Is ARGX or ASND more profitable?

argenx has a net margin of -2.11% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat argenx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Does the MarketBeat Community believe in ARGX or ASND?

argenx received 209 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 67.52% of users gave argenx an outperform vote while only 67.16% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 663 67.52%	Underperform Votes 319 32.48%
Ascendis Pharma A/S	Outperform Votes 454 67.16%	Underperform Votes 222 32.84%

Do analysts rate ARGX or ASND?

argenx currently has a consensus target price of $698.11, suggesting a potential upside of 20.80%. Ascendis Pharma A/S has a consensus target price of $216.07, suggesting a potential upside of 34.81%. Given Ascendis Pharma A/S's higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	3.04
Ascendis Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to ARGX or ASND?

In the previous week, argenx had 18 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 29 mentions for argenx and 11 mentions for Ascendis Pharma A/S. argenx's average media sentiment score of 1.05 beat Ascendis Pharma A/S's score of 0.98 indicating that argenx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	18 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, ARGX or ASND?

argenx has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$2.58B	13.68	-$295.05M	$16.21	35.65
Ascendis Pharma A/S	$368.70M	26.50	-$409.12M	-$6.28	-25.52

Do insiders & institutionals believe in ARGX or ASND?

60.3% of argenx shares are owned by institutional investors. 2.4% of argenx shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

argenx beats Ascendis Pharma A/S on 14 of the 19 factors compared between the two stocks.